Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q2 2024 · 10-Q
Revenue—
Net Income-$783.73K-$783.73KN/M vs Q2 2023 EPS Diluted-$4.02-$4.02N/M vs Q2 2023 Operating Income-$809,665N/M Operating Cash Flowderived-$895,865N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 9, 2024 · 40 d after period end